![Edgewise Therapeutics, Inc. logo](/logos/EWTX.webp)
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Overview | Financials
Company Name | Edgewise Therapeutics, Inc. |
Symbol | EWTX |
Currency | USD |
Price | 17.52 |
Market Cap | 1,642,890,696 |
Dividend Yield | 0% |
52-week-range | 5.12 - 23.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Kevin Koch Ph.D. |
Website | https://www.edgewisetx.com |
An error occurred while fetching data.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD